CARLSBAD, Calif., Dec. 19, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) announced today a new 400 base-pair sequencing kit for the Ion PGM™ Sequencer. The kit produces reads 60 percent longer than comparable high-throughput benchtop sequencers, generating more complete bacterial de novo assemblies with longer contiguous sequences. To see a video about the 400 bp kit and other new products, click here.
"Ion Torrent's long, accurate 400 base pair reads enable excellent bacterial de novo assembly," said Professor Dag Harmsen, Head of Research, Department of Periodontology, University of Muenster, who used the Ion PGM™ Sequencer to help crack the E. coli outbreak in Germany in 2011. "Paired-end sequencing is not required to get the best results."
The Ion PGM™ sequencing 400 kit is ideal for applications that require capturing all the genetic variation in a long exon on a single read. For instance, long reads are critical for researchers trying to interpret genetic data from human leukocyte antigen (HLA) genes or 16S ribosomal genes.
"Sequencing the V1-V2 region of the bacterial 16s rRNA gene would not be possible on the Ion PGM™ without the longer 400 base pair reads," said Dr. George Watts, Research Assistant Professor and Co-Director, Genomic Shared Service, University of Arizona Cancer Center. "Using 400 base pair reads allows us to increase the information density of the amplicons and better define the constituents of complex microbial populations."
Ion Torrent continues to see rapid increases in accuracy on its Ion PGM™ and Ion Proton™ Sequencers as a result of consistent improvements in its algorithms. The new Torrent Suite v3.4 incorporates algorithmic improvements in both raw accuracy and consensus variant calling. These improvements enable both the Ion PGM™ and Ion Proton™ semiconductor sequencing platforms to routinely achieve greater than 99.996 percent consensus accuracy.
Life Technologies is also introducing two additional products, capping a year of extraordinary innovation that made the Ion PGM™ Sequencer the fastest-selling sequencer in the world:
The Ion Torrent products discussed in this press release are for Research Use Only, not for use in diagnostic procedures.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum, with more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, Gibco®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.com.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Corporation
SOURCE Life Technologies